DDD

DANCANN PHARMA A/S

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪8.63 M‬DKK
−0.0190DKK
‪−62.26 M‬DKK
‪6.07 M‬DKK
‪1.03 B‬
Beta (1Y)
3.37

About DANCANN PHARMA A/S


CEO
Jeppe Krog Rasmussen
Headquarters
Ansager
Founded
2018
ISIN
DK0061410487
FIGI
BBG00XRCXP36
DanCann Pharma A/S is a biopharmaceutical company, which engages in the business of discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in various disease areas. It operates under the Biomaterials and Import and Export of Medical Cannabis Products segments. The company was founded by Jeppe Krog Rasmussen on March 20, 2018 and is headquartered in Ansager, Denmark.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of DANCAN is 0.0116 DKK — it has increased by 107.14% in the past 24 hours. Watch DANCANN PHARMA A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NGM exchange DANCANN PHARMA A/S stocks are traded under the ticker DANCAN.
DANCAN stock has risen by 286.67% compared to the previous week, the month change is a 152.17% rise, over the last year DANCANN PHARMA A/S has showed a −73.64% decrease.
DANCAN reached its all-time high on Jan 4, 2022 with the price of 7.0600 DKK, and its all-time low was 0.0028 DKK and was reached on Nov 6, 2024. View more price dynamics on DANCAN chart.
See other stocks reaching their highest and lowest prices.
DANCAN stock is 210.71% volatile and has beta coefficient of 3.37. Track DANCANN PHARMA A/S stock price on the chart and check out the list of the most volatile stocks — is DANCANN PHARMA A/S there?
Today DANCANN PHARMA A/S has the market capitalization of ‪17.88 M‬, it has increased by 64.71% over the last week.
Yes, you can track DANCANN PHARMA A/S financials in yearly and quarterly reports right on TradingView.
DANCANN PHARMA A/S is going to release the next earnings report on Nov 28, 2024. Keep track of upcoming events with our Earnings Calendar.
DANCAN net income for the last quarter is ‪−633.00 K‬ DKK, while the quarter before that showed ‪−2.60 M‬ DKK of net income which accounts for 75.67% change. Track more DANCANN PHARMA A/S financial stats to get the full picture.
No, DANCAN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DANCANN PHARMA A/S EBITDA is ‪−7.18 M‬ DKK, and current EBITDA margin is −216.91%. See more stats in DANCANN PHARMA A/S financial statements.
Like other stocks, DANCAN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DANCANN PHARMA A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DANCANN PHARMA A/S technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DANCANN PHARMA A/S stock shows the sell signal. See more of DANCANN PHARMA A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.